Clinical Interventions in Aging 2013-01-01

Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.

Steven H Ferris, Martin Farlow

Index: Clin. Interv. Aging 8 , 1007-14, (2013)

Full Text: HTML

Abstract

Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.


Related Compounds

Related Articles:

[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].

2014-04-01

[Minerva Med. 105(2) , 167-74, (2014)]

Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.

2013-12-01

[Int. J. Geriatr. Psychiatry 28(12) , 1312-7, (2013)]

Rivastigmine for vascular cognitive impairment.

2013-01-01

[Cochrane Database Syst. Rev. 5 , CD004744, (2013)]

Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.

2013-07-01

[J. Am. Geriatr. Soc. 61(7) , 1170-4, (2013)]

Cholinergic symptoms with low serum cholinesterase from therapeutic cholinesterase inhibitor toxicity.

2014-07-01

[Am. J. Emerg. Med. 32(7) , 815.e3-4, (2014)]

More Articles...